Meta-analysis Based Gene Expression Profiling Reveals Functional Genes in Ovarian Cancer

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2020 Nov 2

PMID 33135729

Citations 11

Authors

Lin Zhao

Yuhui Li

Zhen Zhang

Jing Zou

Jianfu Li

Ran Wei

Qiang Guo

Xiaoxiao Zhu

Chu Chu

Xiaoxiao Fu

Jinbo Yue

Xia Li

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian cancer causes high mortality rate worldwide, and despite numerous attempts, the outcome for patients with ovarian cancer are still not well improved. Microarray-based gene expressional analysis provides with valuable information for discriminating functional genes in ovarian cancer development and progression. However, due to the differences in experimental design, the results varied significantly across individual datasets.

Methods: In the present study, the data of gene expression in ovarian cancer were downloaded from Gene Expression Omnibus (GEO) and 16 studies were included. A meta-analysis based gene expression analysis was performed to identify differentially expressed genes (DEGs). The most differentially expressed genes in our meta-analysis were selected for gene expression and gene function validation.

Results: A total of 972 DEGs with P-value < 0.001 were identified in ovarian cancer, including 541 up-regulated genes and 431 down-regulated genes, among which 92 additional DEGs were found as gained DEGs. Top five up- and down-regulated genes were selected for the validation of gene expression profiling. Among these genes, up-regulated CD24 molecule (CD24), SRY (sex determining region Y)-box transcription factor 17 (SOX17), WFDC2, epithelial cell adhesion molecule (EPCAM), innate immunity activator (INAVA), and down-regulated aldehyde oxidase 1 (AOX1) were revealed to be with consistent expressional patterns in clinical patient samples of ovarian cancer. Gene functional analysis demonstrated that up-regulated WFDC2 and INAVA promoted ovarian cancer cell migration, WFDC2 enhanced cell proliferation, while down-regulated AOX1 was functional in inducing cell apoptosis of ovarian cancer.

Conclusion: Our study shed light on the molecular mechanisms underlying the development of ovarian cancer, and facilitated the understanding of novel diagnostic and therapeutic targets in ovarian cancer.

Citing Articles

Integrative analysis of RNA-sequencing and microarray for the identification of adverse effects of UVB exposure on human skin.

Jang Y, Na H, Shin D, Lee J, Han J, Kim H Front Public Health. 2024; 12:1328089.

PMID: 38444441 PMC: 10913594. DOI: 10.3389/fpubh.2024.1328089.

Identification of Novel Genes and Pathways of Ovarian Cancer Using a Comprehensive Bioinformatic Framework.

Rashid H, Ullah A, Ahmad S, Aljahdali S, Waheed Y, Shaker B Appl Biochem Biotechnol. 2023; 196(6):3056-3075.

PMID: 37615851 DOI: 10.1007/s12010-023-04702-8.

Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis.

Salamini-Montemurri M, Lamas-Maceiras M, Lorenzo-Catoira L, Vizoso-Vazquez A, Barreiro-Alonso A, Rodriguez-Belmonte E Int J Mol Sci. 2023; 24(13).

PMID: 37445988 PMC: 10341812. DOI: 10.3390/ijms241310798.

Comprehensively analyzing the genetic alterations, and identifying key genes in ovarian cancer.

Tang Q, Atiq W, Mahnoor S, Abdel-Maksoud M, Aufy M, Yaz H Oncol Res. 2023; 31(2):141-156.

PMID: 37304238 PMC: 10207953. DOI: 10.32604/or.2023.028548.

CDC20 is a novel biomarker for improved clinical predictions in epithelial ovarian cancer.

Xi X, Cao T, Qian Y, Wang H, Ju S, Chen Y Am J Cancer Res. 2022; 12(7):3303-3317.

PMID: 35968331 PMC: 9360218.

References

Chen Y, Huang L, Wang S, Li J, Li M, Wu Y . contributes to epithelial-mesenchymal transition (EMT) by activating AKT signaling pathway and regulating MMP-2 expression. Cancer Manag Res. 2019; 11:2415-2424. PMC: 6497977. DOI: 10.2147/CMAR.S192950. View

Bowen N, Walker L, Matyunina L, Logani S, Totten K, Benigno B . Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genomics. 2009; 2:71. PMC: 2806370. DOI: 10.1186/1755-8794-2-71. View

Hill C, Matyunina L, Walker D, Benigno B, McDonald J . Transcriptional override: a regulatory network model of indirect responses to modulations in microRNA expression. BMC Syst Biol. 2014; 8:36. PMC: 3987680. DOI: 10.1186/1752-0509-8-36. View

Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter J, Schummer M, McIntosh M . The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003; 63(13):3695-700. View

Tavsan Z, Kayali H . EpCAM-claudin-tetraspanin-modulated ovarian cancer progression and drug resistance. Cell Adh Migr. 2020; 14(1):57-68. PMC: 7757826. DOI: 10.1080/19336918.2020.1732761. View

Yan J, Hedl M, Abraham C . An inflammatory bowel disease-risk variant in INAVA decreases pattern recognition receptor-induced outcomes. J Clin Invest. 2017; 127(6):2192-2205. PMC: 5451247. DOI: 10.1172/JCI86282. View

Gomez-Cabrero D, Abugessaisa I, Maier D, Teschendorff A, Merkenschlager M, Gisel A . Data integration in the era of omics: current and future challenges. BMC Syst Biol. 2014; 8 Suppl 2:I1. PMC: 4101704. DOI: 10.1186/1752-0509-8-S2-I1. View

Elgaaen B, Olstad O, Sandvik L, Odegaard E, Sauer T, Staff A . ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival. PLoS One. 2012; 7(9):e46317. PMC: 3460818. DOI: 10.1371/journal.pone.0046317. View

Merritt M, Parsons P, Newton T, Martyn A, Webb P, Green A . Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer. BMC Cancer. 2009; 9:378. PMC: 2770078. DOI: 10.1186/1471-2407-9-378. View

10.

Moreno C, Matyunina L, Dickerson E, Schubert N, Bowen N, Logani S . Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLoS One. 2007; 2(5):e441. PMC: 1859837. DOI: 10.1371/journal.pone.0000441. View

11.

ODonoghue S, Gavin A, Gehlenborg N, Goodsell D, Heriche J, Nielsen C . Visualizing biological data-now and in the future. Nat Methods. 2010; 7(3 Suppl):S2-4. DOI: 10.1038/nmeth.f.301. View

12.

Tseng G, Ghosh D, Feingold E . Comprehensive literature review and statistical considerations for microarray meta-analysis. Nucleic Acids Res. 2012; 40(9):3785-99. PMC: 3351145. DOI: 10.1093/nar/gkr1265. View

13.

Kitamura S, Sugihara K, Ohta S . Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet. 2006; 21(2):83-98. DOI: 10.2133/dmpk.21.83. View

14.

Zhou W, Wang K, Wang J, Qu J, Du G, Zhang Y . SOX17 Inhibits Tumor Metastasis Via Wnt Signaling In Endometrial Cancer. Onco Targets Ther. 2019; 12:8275-8286. PMC: 6789416. DOI: 10.2147/OTT.S220536. View

15.

Moore R, Hill E, Horan T, Yano N, Kim K, MacLaughlan S . HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. Sci Rep. 2014; 4:3574. PMC: 3880958. DOI: 10.1038/srep03574. View

16.

Johnson W, Li C, Rabinovic A . Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2006; 8(1):118-27. DOI: 10.1093/biostatistics/kxj037. View

17.

Nakamura K, Terai Y, Tanabe A, Ono Y, Hayashi M, Maeda K . CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways. Oncol Rep. 2017; 37(6):3189-3200. PMC: 5442399. DOI: 10.3892/or.2017.5583. View

18.

Haidich A . Meta-analysis in medical research. Hippokratia. 2011; 14(Suppl 1):29-37. PMC: 3049418. View

19.

Ma K, Cao B, Guo M . The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma. Clin Epigenetics. 2016; 8:43. PMC: 4840959. DOI: 10.1186/s13148-016-0210-9. View

20.

Kumar Jha P, Vijay A, Sahu A, Ashraf M . Comprehensive Gene expression meta-analysis and integrated bioinformatic approaches reveal shared signatures between thrombosis and myeloproliferative disorders. Sci Rep. 2016; 6:37099. PMC: 5125005. DOI: 10.1038/srep37099. View